Your browser is no longer supported. Please, upgrade your browser.
Settings
NVAX [NASD]
Novavax, Inc.
Index- P/E- EPS (ttm)-5.22 Insider Own0.10% Shs Outstand63.66M Perf Week-2.31%
Market Cap8.24B Forward P/E7.20 EPS next Y17.64 Insider Trans-86.59% Shs Float62.92M Perf Month2.35%
Income-272.50M PEG- EPS next Q-1.31 Inst Own50.70% Short Float11.65% Perf Quarter39.29%
Sales204.80M P/S40.26 EPS this Y44.90% Inst Trans0.53% Short Ratio1.77 Perf Half Y-9.03%
Book/sh1.73 P/B73.40 EPS next Y421.30% ROA-45.90% Target Price188.50 Perf Year1557.70%
Cash/sh7.76 P/C16.36 EPS next 5Y0.00% ROE- 52W Range6.26 - 189.40 Perf YTD13.87%
Dividend- P/FCF166.56 EPS past 5Y5.60% ROI- 52W High-32.96% Beta1.81
Dividend %- Quick Ratio2.80 Sales past 5Y-9.50% Gross Margin- 52W Low1928.43% ATR9.81
Employees165 Current Ratio2.80 Sales Q/Q6163.40% Oper. Margin- RSI (14)54.36 Volatility7.03% 8.72%
OptionableYes Debt/Eq4.14 EPS Q/Q-332.20% Profit Margin- Rel Volume0.62 Prev Close122.40
ShortableYes LT Debt/Eq3.62 EarningsNov 09 AMC Payout- Avg Volume4.14M Price126.98
Recom2.40 SMA203.97% SMA5010.46% SMA20036.89% Volume2,551,594 Change3.74%
Dec-14-20Initiated Jefferies Buy $200
Aug-06-20Reiterated H.C. Wainwright Buy $132 → $290
Aug-05-20Upgrade JP Morgan Neutral → Overweight $275
Aug-05-20Downgrade Ladenburg Thalmann Neutral → Sell $105
Jul-16-20Reiterated H.C. Wainwright Buy $101 → $132
Jul-08-20Downgrade Ladenburg Thalmann Buy → Neutral $50 → $105
Jun-29-20Reiterated H.C. Wainwright Buy $50 → $101
Jun-29-20Reiterated B. Riley FBR Buy $74 → $106
Jun-05-20Upgrade JP Morgan Underweight → Neutral $46
May-28-20Reiterated B. Riley FBR Buy $53 → $61
May-12-20Reiterated H.C. Wainwright Buy $33 → $50
Apr-30-20Reiterated H.C. Wainwright Buy $24 → $33
Nov-27-19Resumed B. Riley FBR Buy $12
Aug-14-19Reiterated H.C. Wainwright Buy $10 → $17
Feb-28-19Downgrade Piper Jaffray Overweight → Underweight $4.50 → $0.25
Dec-18-18Initiated Ladenburg Thalmann Buy $3
Dec-11-18Initiated Oppenheimer Outperform $4
Nov-26-18Upgrade Piper Jaffray Neutral → Overweight
Sep-21-18Upgrade JP Morgan Underweight → Overweight
Mar-29-18Upgrade Seaport Global Securities Neutral → Buy $5
Jan-22-21 05:23PM  
04:49PM  
08:00AM  
06:25AM  
Jan-20-21 02:08PM  
Jan-19-21 11:05PM  
08:37AM  
Jan-15-21 05:50PM  
12:56PM  
12:47PM  
08:18AM  
08:00AM  
Jan-14-21 04:55PM  
12:27PM  
Jan-13-21 09:42AM  
08:36AM  
06:05AM  
Jan-12-21 09:09AM  
08:54AM  
Jan-11-21 07:37PM  
12:29PM  
07:00AM  
Jan-10-21 07:06AM  
06:06AM  
Jan-08-21 11:50AM  
10:41AM  
09:36AM  
08:42AM  
07:25AM  
06:05AM  
Jan-07-21 06:14PM  
06:30AM  
06:10AM  
Jan-06-21 04:10PM  
11:07AM  
09:15AM  
09:00AM  
Jan-04-21 06:28PM  
10:18AM  
Jan-03-21 06:11AM  
Jan-02-21 06:36AM  
Jan-01-21 06:10AM  
Dec-31-20 08:09AM  
06:31AM  
Dec-30-20 11:40AM  
06:51AM  
06:45AM  
01:04AM  
Dec-29-20 06:19PM  
05:11PM  
10:12AM  
09:34AM  
09:33AM  
09:01AM  
08:38AM  
Dec-28-20 06:13PM  
02:21PM  
11:27AM  
09:31AM  
09:21AM  
09:19AM  
09:15AM  
06:06AM  
Dec-27-20 06:11AM  
Dec-26-20 07:30AM  
07:05AM  
Dec-24-20 12:12PM  
06:14AM  
06:14AM  
Dec-23-20 02:01PM  
Dec-22-20 02:41PM  
01:35PM  
10:35AM  
09:53AM  
06:48AM  
Dec-21-20 05:42PM  
11:55AM  
09:00AM  
05:51AM  
Dec-20-20 06:09AM  
Dec-19-20 06:33AM  
06:09AM  
Dec-18-20 04:47PM  
11:30AM  
07:22AM  
Dec-17-20 12:25PM  
07:00AM  
07:00AM  
06:09AM  
Dec-16-20 07:25PM  
07:08PM  
05:00PM  
09:59AM  
06:14AM  
05:51AM  
Dec-15-20 06:35AM  
06:30AM  
06:11AM  
Dec-14-20 12:11PM  
09:11AM  
Novavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate that in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase III clinical trial for treating seasonal influenza in older adults. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, and the immune systems attack against microorganisms, as well as to allow immunization with much lower doses of antigen. The company is also developing RSV F vaccine for older adults (60 years and older) that is in Phase II clinical trial, as well as for healthy children between six months to five years of age that is in Phase I clinical trial. In addition, it develops nanoparticle vaccine candidates for clinic testing against ebola virus that is in Phase I clinical trial; and combination respiratory vaccine to protect against influenza and RSV. Further, the company is developing COVID-19 vaccine for coronavirus that causes pneumonia-like symptoms, which is in preclinical stage. It has a partnership agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Trizzino JohnEVP, CMO and CBOJan 07Sale124.1750662,830287Jan 07 07:08 PM
Trizzino JohnEVP, CMO and CBOJan 05Option Exercise18.6313,756256,24317,694Jan 07 07:08 PM
Trizzino JohnEVP, CMO and CBOJan 05Sale112.0017,4071,949,522287Jan 07 07:08 PM
YOUNG JAMES FDirectorDec 31Option Exercise51.2711,000564,00011,000Jan 05 05:38 PM
DOUGLAS RICHARDDirectorDec 31Option Exercise50.001,00050,00028,500Jan 05 05:42 PM
YOUNG JAMES FDirectorDec 31Sale113.0911,0001,244,0150Jan 05 05:38 PM
Erck Stanley CPresident and CEONov 16Option Exercise37.1452,3171,942,80172,811Nov 18 06:09 PM
Erck Stanley CPresident and CEONov 16Sale90.6552,3164,742,66720,495Nov 18 06:09 PM
Erck Stanley CPresident and CEOOct 01Sale108.57221720,494Oct 01 05:39 PM
Trizzino JohnEVP, CBO and CFOSep 30Sale110.222,250248,0025,087Oct 01 05:40 PM
Erck Stanley CPresident and CEOSep 30Sale110.2312,2311,348,20020,496Oct 01 05:39 PM
Herrmann John A IIIEVP, Chief Legal OfficerSep 29Sale107.3118,0291,934,667275Sep 30 09:30 PM
Glenn Gregory MPresident, R&DSep 29Sale107.0219,9492,134,8441,561Sep 30 09:29 PM
Trizzino JohnEVP, CBO and CFOSep 29Sale107.2918,3211,965,6307,337Sep 30 09:28 PM
Erck Stanley CPresident and CEOSep 29Sale107.804,112443,26732,727Sep 30 09:27 PM
Erck Stanley CPresident and CEOSep 28Option Exercise5.9550,000297,50074,606Sep 30 09:27 PM
Trizzino JohnEVP, CBO and CFOSep 28Option Exercise5.9529,600176,12053,008Sep 30 09:28 PM
Glenn Gregory MPresident, R&DSep 28Option Exercise5.9525,000148,75046,510Sep 30 09:29 PM
Herrmann John A IIIEVP, Chief Legal OfficerSep 28Option Exercise5.9524,750147,26343,054Sep 30 09:30 PM
Glenn Gregory MPresident, R&DSep 28Sale110.3025,0002,757,45621,510Sep 30 09:29 PM
Trizzino JohnEVP, CBO and CFOSep 28Sale110.3025,0002,757,45625,658Sep 30 09:28 PM
Erck Stanley CPresident and CEOSep 28Sale110.3025,0002,757,45636,839Sep 30 09:27 PM
Herrmann John A IIIEVP, Chief Legal OfficerSep 28Sale110.3024,7502,729,87918,304Sep 30 09:30 PM
EVANS GARY CDirectorAug 18Option Exercise31.0210,500325,700332,479Aug 20 06:09 PM
Glenn Gregory MPresident, R&DAug 18Option Exercise33.5655,9211,876,52557,760Aug 20 06:14 PM
Herrmann John A IIIEVP, Chief Legal OfficerAug 18Option Exercise53.8246,2422,488,61346,517Aug 20 06:20 PM
MCMANUS MICHAEL A JRDirectorAug 18Option Exercise27.608,000220,80017,951Aug 20 06:22 PM
Trizzino JohnEVP, CBO and CFOAug 18Option Exercise50.9542,7882,179,98647,875Aug 20 06:25 PM
Trizzino JohnEVP, CBO and CFOAug 18Sale148.7842,7886,366,1825,087Aug 20 06:25 PM
MCMANUS MICHAEL A JRDirectorAug 18Sale146.008,0001,168,0009,951Aug 20 06:22 PM
Herrmann John A IIIEVP, Chief Legal OfficerAug 18Sale144.3346,2426,673,982275Aug 20 06:20 PM
Glenn Gregory MPresident, R&DAug 18Sale145.2055,9218,119,8601,839Aug 20 06:14 PM
EVANS GARY CDirectorAug 18Sale150.4410,5001,579,620321,979Aug 20 06:09 PM
Glenn Gregory MPresident, R&DJun 18Option Exercise42.2016,749706,80818,588Jun 22 05:29 PM
Glenn Gregory MPresident, R&DJun 18Sale59.5316,749997,1031,839Jun 22 05:29 PM
YOUNG JAMES FDirectorJun 03Buy48.831,50073,2451,500Jun 05 05:04 PM
Herrmann John A IIISVP, General CounselMay 18Option Exercise26.1912,961339,4487,774May 20 04:35 PM
Herrmann John A IIISVP, General CounselMay 18Sale49.4412,961640,792275May 20 04:35 PM
Glenn Gregory MPresident, R&DJan 31Buy3.861,2504,8251,373Feb 04 05:11 PM